银行理财"开门红"未兑现！后续有望承接海量存款配置潮 2026年新年伊始，银行理财存续规模遭遇短暂"寒流"，未兑现"开门红"。2月10日，根据记者从业内可 信渠道汇总的独家数据，管理规模超过1万亿元的14家理财公司（含6家国有行理财、8家股份行理财） 较2025年末下降约8150亿元，再度出现回落。然而，行业仍抱有积极预期：在定期存款利率新低，叠加 海量定期存款集中到期的2026年，理财市场有望受益于居民财富"再配置"。从一线来看，多位银行客户 经理对记者表示，春节前夕银行理财产品销售火爆，部分产品销售破纪录，另外公募基金也迎来销售增 量。（券商中国） 14家理财公司1月末合计规模为24.59万亿元 环比下降约8150亿元 据记者获悉的数据，规模排名靠前的14家理财公司2026年1月末合计规模为24.59万亿元，环比下降约 8150亿元，这也是自2025年11月触及规模峰值以来，连续第2个月出现规模回落。 (证券时报) 制度优化与流动性宽松共振的结果，2026年港股IPO市场预计持续保持热度，增长节奏趋于稳健。（人 民财讯） 私募排排网最新统计数据显示，截至1月底，国内百亿级私募数量达122家，创历史新高，相 ...

证券日报网讯2月10日，和林微纳在互动平台回答投资者提问时表示，公司产品面向全球市场，其中欧 盟是公司重要市场之一，公司有瑞士全资子公司，其主要从事微型自动化设备的研发与生产，当前公司 主要以境内主体直接向欧盟客户出口为主。 ...

证券日报网讯2月10日，和林微纳在互动平台回答投资者提问时表示，AMD为公司重要客户之一，公司 与其相关业务稳步开展。 ...

（文章来源：证券日报） 证券日报网讯 2月10日，和林微纳在互动平台回答投资者提问时表示，截至2026年1月10日公司股东数 为9263户。 ...

Investment Performance - The January stock portfolio achieved a return of +15.42%, outperforming the Shanghai Composite Index and CSI 300 Index by 13.77 percentage points and 8.31 percentage points respectively [2] - The portfolio included one Hong Kong stock with a return of 11.04%, while the Hang Seng Index rose by 6.85% [2] - The top-performing sectors included non-ferrous metals (+23%), media (+18%), and oil and petrochemicals (+16%) [2] February Investment Strategy Outlook - The A-share market has seen increased volatility since late January, influenced by valuation levels and external factors such as precious metals and the US dollar index [3] - The strategy suggests selecting stocks with solid fundamentals and low implied expectations, while maintaining a balanced portfolio to avoid overexposure to any single sector [3] - Key indicators to monitor include the trends in precious metals, the US dollar index, and A-share market trading volume [3] February Stock Recommendations Power Equipment and New Energy - Zhongtian Technology (600522.SH) is recommended due to its leadership in optical fiber and expected benefits from increased demand driven by AI investments and a significant investment plan from the State Grid [5][6] Electronics - Helin Micro-Nano (688661.SH) is favored for its potential growth in the chip testing market, driven by increased complexity and demand for FT probes [7] Robotics - Amperelong (301413.SZ) is highlighted for its expansion in automotive sensor products and its role in the emerging field of humanoid robots [9][10] Media - Alibaba-W (09988.HK) is recommended due to its rapid growth in cloud services and AI-related products, with a significant market share in China's public cloud IaaS market [12][13] Transportation - Southern Airlines (600029.SH) is positioned to benefit from high capacity and operational efficiency, with a projected increase in passenger volume [14] New Materials - Huafeng Aluminum (601702.SH) is expected to benefit from the demand for aluminum materials in the new energy vehicle sector and the trend of "aluminum replacing copper" [16] Building Materials - China Jushi (600176.SH) is recommended as it is positioned to benefit from a market shift in electronic fabrics and the ongoing demand for fiberglass [17] Real Estate - China Merchants Shekou (001979.SZ) is favored for its strong asset structure optimization and focus on core cities, which positions it well in the current market environment [18] Non-Banking Financials - China Life (601628.SH) is expected to perform well in 2026, with strong sales and investment returns [19] North Exchange - Haixi Communications (920405.BJ) is recommended due to its expanding energy storage business and stable traditional operations [22]

Investment Rating - The report maintains a strong rating for the pharmaceutical sector, indicating it is expected to outperform the market [6]. Core Insights - The targeted PAM pathway represents a potential market of approximately $10 billion, with significant implications for breast and prostate cancer treatments [4][16]. - Celcuity's Gedatolisib is highlighted as a promising PAM inhibitor, showing comparable efficacy to existing therapies and is under FDA priority review with a PDUFA date set for July 17, 2026 [4][37]. - The report emphasizes the importance of innovation and international expansion in the pharmaceutical industry, suggesting that companies focusing on these areas will likely thrive [4]. Summary by Sections Targeted PAM Pathway - The PAM pathway is identified as one of the most underdeveloped targets in solid tumors, with mutations occurring in 38% of cancer patients [4][16]. - Gedatolisib is noted for its effectiveness across various PI3K subtypes and its potential to establish new treatment standards in HR+/HER2- advanced breast cancer [25][37]. - HMPL-A251, developed by Hutchison China MediTech, is a HER2-targeted PAM inhibitor that has shown strong anti-tumor activity in both HER2-positive and low-expressing tumors [41][50]. Market Review and Trends - The report reviews the performance of the pharmaceutical sector from January 26 to January 30, 2026, noting a decline of 3.3% in the CITIC Pharmaceutical Index, which underperformed the CSI 300 Index by 3.4 percentage points [3][60]. - The report highlights the best-performing stocks during this period, including Cap Bio (+26.5%) and Hualan Biological (+12.8%) [3][74]. - The overall valuation of the pharmaceutical sector as of January 30, 2026, is reported at 29.09, reflecting a slight decrease of 0.87% [69].

2026年1月29日，截至收盘，沪指涨0.16%，报收4157.98点；深成指跌0.3%，报收14300.08点；创业板 指跌0.57%，报收3304.51点。科创半导体ETF（588170）跌4.39%，半导体设备ETF华夏（562590）跌 4.39%。 3.和林微纳(688661.SH)公告称，预计2025年归属于上市公司股东的净利润为2600万元至3300万元，同比 扭亏为盈；扣除非经常性损益的净利润为2200万元至2700万元。报告期内，全球高性能算力芯片量产规 模增长，测试复杂度提升带动高规格FT测试探针需求增加，公司核心产品技术匹配度高、订单稳步释 放，业务结构优化推动业绩增长。 中信建投指出，受AI需求爆发、供给侧收缩等多重因素影响，存储芯片正处于价格上升期，推动全球 存储产业链企业迎来业绩爆发。存储产线建设及国产化率提升有望进入加速阶段，看好配套半导体设 备、封测等国内存储链投资机遇。随着国产替代逻辑加强、存储产能扩张，新一轮资本开支周期下国产 设备/零部件/材料将深度受益。 相关ETF：公开信息显示， 科创半导体ETF（588170）及其联接基金（A类：024417；C类：024418） ...

Core Insights - The article highlights significant profit forecasts for various companies in 2025, indicating a trend of recovery and growth across multiple sectors, with some companies projecting substantial increases in net profit compared to the previous year. Company Performance Forecasts - **Beimo High-Tech**: Expected net profit for 2025 is between 190 million to 220 million yuan, a year-on-year increase of 1076.16% to 1261.87% [2] - **Jiangfeng Electronics**: Plans to acquire control of Kaide Quartz, with stock suspension starting January 30 [3] - **ST Aowei**: Received a notice of termination of listing due to market capitalization falling below 500 million yuan for 20 consecutive trading days [4] - **GaoDe Infrared**: Forecasted net profit of 700 million to 900 million yuan for 2025, recovering from a loss of 447 million yuan in the previous year [6] - **Bingchuan Network**: Expected net profit of 436 million to 516 million yuan, recovering from a loss of 247 million yuan [6] - **BlueFocus**: Anticipated net profit of 180 million to 220 million yuan, recovering from a loss of 291 million yuan [7] - **Godewei**: Projected net profit of 125 million to 162 million yuan, turning from loss to profit [6] - **Zhongyida**: Expected net profit of 51.23 million yuan, recovering from a loss [8] - **Helin Micro-Nano**: Forecasted net profit of 26 million to 33 million yuan, turning from loss to profit [8] - **Zhongke Sanhuan**: Expected net profit of 80 million to 120 million yuan, a year-on-year increase of 566.23% to 899.35% [9] - **Beilu Pharmaceutical**: Projected net profit of 87 million to 130 million yuan, a year-on-year increase of 537.28% to 852.26% [9] - **Light Media**: Expected net profit of 1.5 billion to 1.9 billion yuan, a year-on-year increase of 413.67% to 550.66% [9] - **Zhezhong Co.**: Forecasted net profit of 360 million to 500 million yuan, a year-on-year increase of 392.14% to 583.53% [10] - **Hailanxin**: Expected net profit of 40 million to 60 million yuan, a year-on-year increase of 387.47% to 631.2% [10] - **Jin Control Power**: Projected net profit of 155 million to 195 million yuan, a year-on-year increase of 383.21% to 507.9% [11] - **Century Huatong**: Expected net profit of 5.55 billion to 6.98 billion yuan, a year-on-year increase of 357.47% to 475.34% [12] - **Chunxue Food**: Forecasted net profit of 36 million to 43 million yuan, a year-on-year increase of 340.90% to 426.63% [13] - **Shirong Zhaoye**: Expected net profit of 126 million to 186 million yuan, a year-on-year increase of 236.77% to 397.13% [13] - **Ningbo Yunsheng**: Projected net profit of 280 million to 380 million yuan, a year-on-year increase of 194.49% to 299.67% [14] - **Jiangbolong**: Expected net profit of 1.25 billion to 1.55 billion yuan, a year-on-year increase of 150.66% to 210.82% [16] - **China Shipbuilding**: Forecasted net profit of 7 billion to 8.4 billion yuan, a year-on-year increase of 65.89% to 99.07% [17] Fundraising and Restructuring - **Beijing Lier**: Plans to raise no more than 1.034 billion yuan through a private placement [21] - **Tongfei Co.**: Plans to raise no more than 1.2 billion yuan through a private placement [21] - **Muxi Co.**: Plans to provide up to 200 million yuan in loans to its subsidiary for GPU development [23] - **Wanhua High-Tech**: Haihua Group will become an indirect controlling shareholder through a cash increase of 4.998 billion yuan [23]

公司作为全球算力芯片供应链的供应商，报告期内，核心产品FT测试探针紧跟客户的技术标准升级， 有效匹配了新一代高性能芯片在成品测试环节对物理精度及电学性能等方面的要求。由于高性能芯片测 试位点及单次测试周期的变化，FT测试探针作为关键耗材的单位消耗量及周转频率有所提升，公司在 既有供应体系内的订单规模稳步释放。此外，公司通过保障高规格产品的持续供应与技术响应，支撑了 下游客户高性能芯片在量产阶段的测试效率，整体业务结构得到进一步的优化，从而带动了本年度公司 经营业绩的增长。 报告期内，全球半导体行业高性能算力领域的技术迭代持续推进，相关芯片产品的量产规模逐步增长。 随着芯片制程工艺与封装集成度的不断演进，成品测试(FT)环节的测试复杂度随之提升，对测试信号的 传输质量及测试环境的稳定性提出了更高层级的技术要求。受此影响，产业链后端测试环节对高规格精 密测试探针等耗材的需求结构发生变化，技术规格的升级成为驱动相关精微零部件需求增长的主要因 素。 智通财经APP讯，和林微纳(688661.SH)发布2025年年度业绩预告，预计2025年年度实现归属于母公司 所有者的净利润为2600万元到3300万元，将实现扭亏为盈 ...

公司作为全球算力芯片供应链的供应商，报告期内，核心产品FT测试探针紧跟客户的技术标准升级， 有效匹配了新一代高性能芯片在成品测试环节对物理精度及电学性能等方面的要求。由于高性能芯片测 试位点及单次测试周期的变化，FT测试探针作为关键耗材的单位消耗量及周转频率有所提升，公司在 既有供应体系内的订单规模稳步释放。此外，公司通过保障高规格产品的持续供应与技术响应，支撑了 下游客户高性能芯片在量产阶段的测试效率，整体业务结构得到进一步的优化，从而带动了本年度公司 经营业绩的增长。 报告期内，全球半导体行业高性能算力领域的技术迭代持续推进，相关芯片产品的量产规模逐步增长。 随着芯片制程工艺与封装集成度的不断演进，成品测试(FT)环节的测试复杂度随之提升，对测试信号的 传输质量及测试环境的稳定性提出了更高层级的技术要求。受此影响，产业链后端测试环节对高规格精 密测试探针等耗材的需求结构发生变化，技术规格的升级成为驱动相关精微零部件需求增长的主要因 素。 和林微纳(688661.SH)发布2025年年度业绩预告，预计2025年年度实现归属于母公司所有者的净利润为 2600万元到3300万元，将实现扭亏为盈。 ...